ssr-69071 and Inflammation

ssr-69071 has been researched along with Inflammation* in 1 studies

Other Studies

1 other study(ies) available for ssr-69071 and Inflammation

Article	Year
A novel orally active inhibitor of HLE. European journal of medicinal chemistry, 2003, Volume: 38, Issue:4 Human leukocyte elastase (HLE) is a serine proteinase, capable of degrading a variety of structural matrix proteins. SSR69071 2-[(4-isopropyl-6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methoxy]-9-(2-piperidin-1-ylethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one was selected as a novel orally active HLE inhibitor for treatment of chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis and several inflammatory diseases (WO 01/44245 A1) (J. Pharm. Exp. Ther., submitted for publication). Topics: Administration, Oral; Animals; Asthma; Cyclic S-Oxides; Cystic Fibrosis; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hemorrhage; Humans; Inflammation; Leukocyte Elastase; Lung Diseases, Obstructive; Mice; Models, Chemical; Pulmonary Emphysema; Thiazoles	2003

Article

Year

European journal of medicinal chemistry, 2003, Volume: 38, Issue:4

Human leukocyte elastase (HLE) is a serine proteinase, capable of degrading a variety of structural matrix proteins. SSR69071 2-[(4-isopropyl-6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methoxy]-9-(2-piperidin-1-ylethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one was selected as a novel orally active HLE inhibitor for treatment of chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis and several inflammatory diseases (WO 01/44245 A1) (J. Pharm. Exp. Ther., submitted for publication).

Topics: Administration, Oral; Animals; Asthma; Cyclic S-Oxides; Cystic Fibrosis; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hemorrhage; Humans; Inflammation; Leukocyte Elastase; Lung Diseases, Obstructive; Mice; Models, Chemical; Pulmonary Emphysema; Thiazoles

2003